Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mavorixafor + nivolumab
- Development stage
- Discontinued
- Lead developer
- X4 Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of **mavorixafor (X4P-001)**, an orally bioavailable, selective, allosteric inhibitor of the chemokine receptor **CXCR4**, and **nivolumab**, a PD-1-targeting immune checkpoint inhibitor monoclonal antibody. Mavorixafor blocks the CXCR4/CXCL12 axis, disrupting recruitment of immunosuppressive cells and increasing cytotoxic T cell infiltration in the tumor microenvironment. Nivolumab blocks PD-1 on T cells, enhancing antitumor immunity by preventing tumor-induced T cell inactivation. This combination is being investigated primarily for advanced clear cell renal cell carcinoma (ccRCC) in patients who did not respond to nivolumab monotherapy, with evidence of immune modulation and tumor immune infiltration. Developed by X4 Pharmaceuticals.
- Other names
- X4P-001 + nivolumab
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on mavorixafor + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mavorixafor + nivolumab.